Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company’s focus on improving the therapeutic index of CTLA-4 inhibition through its proprietary masking technology.
Chane-Du described Adagene as a global biotechnology company developing novel antibodies, including monoclonal antibodies, T-cell engagers, antibody-drug conjugates and masked versions of those formats. Its lead program, ADG126, also known as muzastotug, is a masked anti-CTLA-4 antibody that the company believes has shown preliminary evidence of an improved therapeutic index compared with first-generation anti-CTLA-4 therapies.
